Skip to content
Roboearth – Lifestyle
Author:
Mabwell (Shanghai) Bioscience Co., Ltd.
Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
May 21, 2026
Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection)
May 20, 2026
World’s First | Mabwell’s 9MW5211 Receives FDA Clearance for Clinical Trial Application
May 8, 2026
2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
April 30, 2026
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
April 23, 2026
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
April 23, 2026
Case Report of Mabwell’s Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
April 21, 2026
Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
April 20, 2026
Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market
April 16, 2026
Global First | NMPA Accepts IND Application for Mabwell’s Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
April 15, 2026
1
2
Next Page
→